Ameriprise Financial Inc. Has $4.04 Million Position in Diplomat Pharmacy, Inc. (DPLO)

Ameriprise Financial Inc. raised its stake in shares of Diplomat Pharmacy, Inc. (NYSE:DPLO) by 19.3% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 272,979 shares of the company’s stock after buying an additional 44,135 shares during the quarter. Ameriprise Financial Inc. owned about 0.41% of Diplomat Pharmacy worth $4,043,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. increased its stake in shares of Diplomat Pharmacy by 73.1% during the first quarter. JPMorgan Chase & Co. now owns 7,235 shares of the company’s stock valued at $116,000 after buying an additional 3,056 shares during the period. State of Alaska Department of Revenue grew its stake in Diplomat Pharmacy by 80.0% in the second quarter. State of Alaska Department of Revenue now owns 8,623 shares of the company’s stock worth $127,000 after purchasing an additional 3,833 shares during the period. Mason Street Advisors LLC grew its stake in Diplomat Pharmacy by 8.4% in the first quarter. Mason Street Advisors LLC now owns 10,148 shares of the company’s stock worth $162,000 after purchasing an additional 783 shares during the period. Municipal Employees Retirement System of Michigan grew its stake in Diplomat Pharmacy by 4.9% in the second quarter. Municipal Employees Retirement System of Michigan now owns 10,250 shares of the company’s stock worth $152,000 after purchasing an additional 480 shares during the period. Finally, Janney Montgomery Scott LLC grew its stake in shares of Diplomat Pharmacy by 11.9% in the second quarter. Janney Montgomery Scott LLC now owns 11,193 shares of the company’s stock worth $166,000 after acquiring an additional 1,193 shares during the last quarter. Institutional investors own 67.36% of the company’s stock.

Shares of Diplomat Pharmacy, Inc. (DPLO) traded down $0.53 during mid-day trading on Friday, reaching $19.66. The company had a trading volume of 333,700 shares, compared to its average volume of 785,191. Diplomat Pharmacy, Inc. has a 1 year low of $12.25 and a 1 year high of $21.99. The company has a current ratio of 1.34, a quick ratio of 0.88 and a debt-to-equity ratio of 0.18. The stock has a market cap of $1,320.00, a P/E ratio of 26.22, a price-to-earnings-growth ratio of 3.63 and a beta of 0.74.

Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Monday, November 6th. The company reported $0.25 EPS for the quarter, topping the Zacks’ consensus estimate of $0.15 by $0.10. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same quarter in the previous year, the firm posted $0.21 EPS. The firm’s revenue was down 4.8% compared to the same quarter last year. sell-side analysts predict that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current year.

Several research firms recently issued reports on DPLO. TheStreet upgraded Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research report on Thursday, August 10th. Mizuho set a $16.00 price objective on Diplomat Pharmacy and gave the company a “hold” rating in a research note on Tuesday, October 24th. Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Needham & Company LLC raised their price objective on Diplomat Pharmacy from $23.75 to $24.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, BidaskClub lowered Diplomat Pharmacy from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Diplomat Pharmacy currently has an average rating of “Hold” and a consensus target price of $20.06.

WARNING: “Ameriprise Financial Inc. Has $4.04 Million Position in Diplomat Pharmacy, Inc. (DPLO)” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/11/diplomat-pharmacy-inc-dplo-shares-bought-by-ameriprise-financial-inc.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Institutional Ownership by Quarter for Diplomat Pharmacy (NYSE:DPLO)

Receive News & Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply